Organovo's shares were off to a good start after the company reported results from its fiscal second quarter. Here's a look at the highlights from the report.
- Revenue grew 358% over the year-ago period to $1.4 million. Included in that total was $400,000 in collaborations and grant revenue received by pharma giant Merck.
- Net loss was $9.4 million, or $0.10 per share. That was an improvement over the $11.3 million loss that was reported in the same quarter last year and was slightly better than the $0.11 loss that Wall Street had expected.
- Ten of the top 25 global pharmaceutical companies are now using Organovo's products.
- Organovo's new ExVive Human Kidney Tissue service is doing well so far. Management said that it received "multiple orders" since it launched two months ago, two of which came from top 25 global pharma companies.
- The company ended the quarter with $51.7 million in cash, but that figure doesn't include the roughly $25 million generated from a recently completed secondary offering.
Management also reaffirmed its fiscal-year 2017 outlook in the report, which calls for the following:
$4.5 million-$6.2 million
Net Cash Utilization
$31.0 million-$34.0 million
Finally, CEO Keith Murphy issued an even more bullish outlook when he presented at the Piper Jaffray Healthcare Conference at the end of the month. Murphy stated that he believes the Organovo will be able to grow at triple-digit rates for years to come.
Add all of the above to the general rally in the biotech sector from the surprise election of Donald Trump, and it is easy to see why shares rose in November.
The prospect of triple-digit sales growth for the foreseeable future is certainly quite exciting. It might not even be all that hard to pull off given the positive start for the company's ExVive Human Kidney Tissue service. With its partnership with Merck and a balance sheet that is flush with cash, no wonder investors are feeling bullish.
Then again, Organovo has always been long on potential, but financial results had always been tepid at best. Even assuming strong growth into next year, the company is only projecting about $5 million in total. With a current market cap that exceeds $330 million, Organovo's price-to-sales ratio is currently in the stratosphere. That could be one reason why the company had to offer a discount on its shares in its recent dilutive offering to drum up enough demand for them.
In total, I continue to believe that Organovo is a fascinating company to watch, but it is far too speculative to warrant an investment. I'd be happy to change my tune once we have a sense for when profits could be on the horizon, but for now, I think that caution is the right move.